Natural killer cell alloreactivity in allogeneic hematopoietic transplantation

Purpose of review This review will focus on the translation of natural killer cell recognition of missing self into the clinical practice of allogeneic hematopoietic transplantation and discuss how it has opened innovative perspectives in the cure of leukemia. Allogeneic hematopoietic stem cell transplantation from a human leukocyte antigen-matched sibling can cure leukemia but 75% of patients do not have a matched donor, one alternative source of stem cells includes full haplotype mismatched family members. As haploidentical transplantation must be extensively T cell depleted to prevent lethal graft-versus-host disease, it cannot rely on donor T cells for the graft-versus-leukemia effect. Mismatched transplantation, however, triggers alloreactivity mediated by natural killer cells which is based upon ‘missing self recognition’. Recent studies Recent studies using preclinical murine models of haploidentical transplantation demonstrated that conditioning with alloreactive natural killer cells ablates the recipient immune system and leukemia cells. In the clinical setting of mismatched hematopoietic stem cell transplantation, donor versus recipient natural killer cell alloreactivity has been associated with better outcome, particularly in patients with acute myeloid leukemia who are transplanted in remission. Summary Given the benefits of natural killer cell alloreactivity, it is expected that it will encourage greater use of haploidentical transplants for the large numbers of leukemia patients without matched donors.

[1]  M. Bennett,et al.  PECULIAR IMMUNOBIOLOGY OF BONE MARROW ALLOGRAFTS , 1971, Journal of Experimental Medicine.

[2]  IMMUNOLOGIC MEMORY CELLS OF BONE MARROW ORIGIN , 1972, The Journal of experimental medicine.

[3]  W. Murphy,et al.  Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection , 1987, The Journal of experimental medicine.

[4]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.

[5]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.

[6]  J. Dorfman,et al.  The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. , 1996, Immunity.

[7]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[8]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[9]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.

[10]  J. Roberts,et al.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. , 1999, The New England journal of medicine.

[11]  Todd A Fehniger,et al.  Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. , 2002, Blood.

[12]  Heather G. Shilling,et al.  Genetic Control of Human NK Cell Repertoire1 , 2002, The Journal of Immunology.

[13]  NK cells: a lesson from mismatched hematopoietic transplantation. , 2002 .

[14]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[15]  Daniel J Weisdorf,et al.  Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. , 2002, Blood.

[16]  R. Handgretinger,et al.  T‐cell alloreactivity dominates natural killer cell alloreactivity in minimally T‐cell‐depleted HLA‐non‐identical paediatric bone marrow transplantation , 2003, British journal of haematology.

[17]  P. Parham,et al.  The Protein Made from a Common Allele of KIR3DL1 (3DL1*004) Is Poorly Expressed at Cell Surfaces due to Substitution at Positions 86 in Ig Domain 0 and 182 in Ig Domain 1 1 , 2003, The Journal of Immunology.

[18]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[19]  J. Luhm,et al.  NK cells: a lesson from mismatched hematopoietic transplantation. , 2003, Trends in immunology.

[20]  G. Ehninger,et al.  Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. , 2004, Blood.

[21]  J. P. McCoy,et al.  Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. , 2004, Blood.

[22]  R. Biassoni,et al.  Structure of the Ly49 family of natural killer (NK) cell receptors and their interaction with MHC class I molecules , 2004, Immunologic research.

[23]  The Immune System in Graft-vs.-Host Disease: Target and Effector Organ , 2004 .

[24]  J. Cahn Clinical bone marrow and blood stem cell transplantation , 2004, Leukemia.

[25]  L. Lanier,et al.  Function of NKG2D in natural killer cell–mediated rejection of mouse bone marrow grafts , 2005, Nature Immunology.

[26]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[27]  N. Kröger,et al.  Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR‐ligand mismatch after dose‐reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma , 2005, British journal of haematology.

[28]  C. Mecucci,et al.  Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Velardi,et al.  Hematopoietic Cell Transplantation from HLA Partially Matched Related Donors , 2007 .